Related Experiment Video
Updated: Aug 23, 2026
Strategies for Study of Neuroprotection from Cold-preconditioning
Published on: September 2, 2010
Lost in translation: taking neuroprotection from animal models to clinical trials
1Calgary Stroke Program, Department of Clinical Neurosciences, University of Calgary, AB, Canada T2N 2T8.
Abstract:
Caffeinol has been proposed as a neuroprotectant for human trials. This review covers a variety of animal models used and various attempts to take animal protocols to human trials. The accompanying paper discusses the rabbit model that was used to identify the efficacy of tissue plasminogen activator (tPA) treatment. To date, this is the only model that was able to achieve laboratory to clinical translational success. Use of caffeinol as a cytoprotective agent in rat models yielded exciting results, which led to clinical trials. However, caffeinol given with tPA in rabbits leads to increased hemorrhage. Caffeinol alone does not prove to be neuroprotective, as vasodilation by itself is not efficacious. However, vasodilation combined with thrombolysis (caffeinol with tPA) poses an increased risk of hemorrhage. For a more translational approach to study neuroprotection and neuroprotective agents in human trials, it is necessary to demonstrate the efficacy of the procedure and purported agents in several animal models.
Insights
Caffeinol shows potential as a neuroprotectant but requires validation in multiple animal models. Combining caffeinol with tissue plasminogen activator (tPA) increases hemorrhage risk, highlighting the need for careful study in neuroprotection research.
Area of Science:
- Neuroscience
- Pharmacology
- Translational Medicine
Background:
- Caffeinol has been investigated as a potential neuroprotectant for human clinical trials.
- Previous studies explored its efficacy in various animal models, with mixed results.
- Translational success from animal models to human trials remains a significant challenge in neuroprotection research.
Purpose of the Study:
- To review animal models used in neuroprotection research.
- To evaluate the translational potential of caffeinol as a neuroprotective agent.
- To assess the safety and efficacy of combining caffeinol with tissue plasminogen activator (tPA).
Main Methods:
- Review of existing literature on animal models for neuroprotection.
- Analysis of studies using caffeinol in rat and rabbit models.
- Examination of clinical trial data stemming from animal studies.
Main Results:
- The rabbit model demonstrated translational success for tissue plasminogen activator (tPA) treatment.
- Caffeinol as a cytoprotective agent showed promise in rat models, leading to clinical trials.
- Combining caffeinol with tPA in rabbits resulted in increased hemorrhage; caffeinol alone was not neuroprotective due to vasodilation's limited efficacy.
Conclusions:
- Caffeinol alone is not neuroprotective; vasodilation is insufficient.
- The combination of caffeinol and tPA increases hemorrhage risk, limiting its therapeutic window.
- Demonstrating efficacy across multiple animal models is crucial for advancing neuroprotective agents into human trials.
